Cost-effectiveness of 20-valent pneumococcal conjugate vaccine in Denmark compared with PPV23.
Jens OlsenHenrik SchnackMette SkovdalJeffrey VietriMalene Buch MikkelsenPeter Bo PoulsenPublished in: Journal of medical economics (2022)
Vaccination with PCV20 reduced the incidence and mortality of pneumococcal diseases in Danish adults compared to PPV23. This reduction has the potential to reduce the financial burden related to managing diseases while also increasing public health.